Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Wednesday, March 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced the receipt of two U.S. patent allowances for its PBGENE-HBV program. This development highlights the company's innovative ARCUS platform, which focuses on in vivo gene editing therapies for diseases with high unmet needs. The patents are expected to strengthen the company's position in the gene editing market.
Price reaction · baseline $5.35 (2026-03-10 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close
-5.4%
day 1
+6%
day 3 · peak
+17.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences received U.S. patent allowances.
  • The patents cover the PBGENE-HBV program.
  • The ARCUS platform is positioned for in vivo gene editing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Mar. 11, 2026– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices

Frequently Asked Questions

What is the PBGENE-HBV program?

The PBGENE-HBV program focuses on developing gene editing therapies for Hepatitis B.

What technology does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

What recent achievement did Precision BioSciences announce?

The company announced the receipt of U.S. patent allowances for its PBGENE-HBV program.

How does the patent impact Precision BioSciences?

The patent allowances are expected to strengthen the company's position in the gene editing market.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences PBGENE-HBV gene editing U.S. patent ARCUS platform
Last updated: Mar 11, 2026

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →